Alaunos Therapeutics Inc

NASDAQ:TCRT   4:00:00 PM EDT
0.67
0.00 (-0.58%)
7:09:03 PM EDT: $0.68 +0.01 (+2.12%)
Earnings Announcements

Alaunos Therapeutics Reports Q3 2022 Financial Results

Published: 11/14/2022 12:58 GMT
Alaunos Therapeutics Inc (TCRT) - Alaunos Therapeutics Reports Third Quarter 2022 Financial Results.
Q3 Loss per Share $0.04.
Actively Enrolling Patients in Tcr-t Library Phase 1/2 Trial at Second Dose Level; Expect to Treat Next Patient in 4q22.
Alaunos Therapeutics - to File Ind Amendment in 4q22 to Add 2additional Tcrs to Tcr Library and Move From Fresh to Cryopreserved Manufacturing Process.
Collaboration Revenue Was $2.9 Million for Q3 of 2022, Compared to $0.4 Million for Q3 of 2021.
Q3 Earnings per Share View $-0.08, Revenue View $0.00 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.05

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.05

More details on our Analysts Page.